Patents Assigned to LB PHARMACEUTICALS INC.
-
Patent number: 11713295Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: June 21, 2021Date of Patent: August 1, 2023Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 11377421Abstract: The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of serotonin in the brain, either individually or in combination with one or more other CNS active agents.Type: GrantFiled: September 23, 2019Date of Patent: July 5, 2022Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 11040943Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: September 5, 2019Date of Patent: June 22, 2021Assignee: LB Pharmaceuticals Inc.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 10689338Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: September 5, 2019Date of Patent: June 23, 2020Assignee: LB Pharmaceuticals Inc.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Publication number: 20200123102Abstract: The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptor in a subject, either individually or in combination with one or more other CNS active agents. The R enantiomer of amisulpride and amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of serotonin in the brain, either individually or in combination with one or more other CNS active agents.Type: ApplicationFiled: September 23, 2019Publication date: April 23, 2020Applicant: LB PHARMACEUTICALS INC.Inventors: Andrew R. VAINO, Vincent T. GRATTAN, Zachary PRENSKY
-
Patent number: 10259786Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more disorders associated with an abnormality in levels of dopamine and/or serotonin in the brain.Type: GrantFiled: November 28, 2017Date of Patent: April 16, 2019Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky
-
Patent number: 10167256Abstract: Novel amisulpride derivatives and pharmaceutical compositions thereof are disclosed. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may have better membrane permeability compared to amisulpride. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for antagonizing dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents. The amisulpride derivative disclosed herein or a pharmaceutical composition thereof may be used for treating one or more conditions responsive to modulation of dopamine and/or serotonin (e.g., 5-HT2a) and/or ?2 receptor in a subject, either individually or in combination with other CNS active agents.Type: GrantFiled: February 14, 2018Date of Patent: January 1, 2019Assignee: LB PHARMACEUTICALS INC.Inventors: Andrew R. Vaino, Vincent T. Grattan, Zachary Prensky